Carisbamate

Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy^[1][2][3]. In Vitro:Carisbamate (200 µM; 12 h) exhibits antiepileptic effects on SREDs model of hippocampal cells^[1].
Carisbamate (200 µM; 24 h) shows long lasting effects on the hippocampal neurons that are independent from antiepileptic effects in vitro^[1].
Carisbamate not only inhibits the development and expression of SREDs in the majority of neurons, but also decreases seizure frequency and duration in the few neurons that still has an occasional epileptiform event^[1].
Carisbamate (200 µM) shows neuroprotective effects on hippocampal cells with SE (status epilepticus)-like injury^[1]. In Vivo:Carisbamate (10, 30, 60 mg/kg; i.p.; single) dose dependently reduces the expression of spike-and-wave discharges (SWD) in absence seizures rat model^[2].
Carisbamate (20, 30 mg/kg; i.p.; single) shows no wild running episode or tonic seizure occurres in any of the rats tested^[2].